Table 2.

Combination agent PARIS^® test results.

Drug	Target	C max	IC50	Single agent AUC	Fulvestrant combination AUC	Absolute difference AUC
Everolimus	mTORC1	3.90E−08	7.60E−06	0.63	0.53	0.11
Lapatinib	EGFR, HER2	4.00E−06	1.30E−06	0.55	0.44	0.10
Ribociclib	CDK4, CDK6	7.10E−06	1.30E−06	0.6	0.51	0.09
Neratinib	EGFR, HER1, HER2, HER4	2.14E−07	8.50E−08	0.43	0.37	0.06

PARIS^® testing using a combination of fulvestrant at 1 μM, the pretested IC₃₀ concentration for this PDTO, along with either everolimus, lapatinib, ribociclib, or neratinib. The combinations are ranked by the largest differential area under the curve (AUC) obtained using six concentrations of each drug (10 μM, 3.16 μM, 1 μM, 316 nM, 100 nM, and 31.6 nM). Only the drugs that had enhanced activity with fulvestrant are shown.